Exercise of Options and Total Voting Rights

RNS Number : 9673M

Redx Pharma plc

27 September 2021

 

REDX PHARMA PLC

("Redx" or "the Company")

Exercise of Options and Total Voting Rights

Alderley Park, 27 September 2021,  Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces the exercise of share options by a former employee of the Company over 500,000 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at exercise prices of 22 pence (166,666 shares), 33 pence (166,667 shares) and 50 pence (166,667 shares) per share respectively.

Application has been made to the London Stock Exchange for the 500,000 new Ordinary Shares to be admitted to trading on AIM and admission is expected to occur on or around 8.00am on 28 September 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 275,282,205 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

For further information, please contact:
Redx Pharma Plc	T: [phone]
Peter Presland, Interim Chairman Lisa Anson, Chief Executive Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser)	T: [phone]
Matt Davis/Adam Dawes
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker)	T: [phone]
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting	T: [phone]
Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, the Porcupine inhibitor RXC004, is expected to commence a Phase 2 programme in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.   

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, with five proprietary or partnered assets in late pre-clinical or clinical development. One of those assets, a BTK inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now Eli Lilly) and is currently in Phase 3 clinical studies in chronic lymphocytic leukaemia. In addition, Redx has forged pre-clinical asset partnerships with other blue chip companies including AstraZeneca and Jazz Pharmaceuticals.   

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/  

 

END

 

 

MSCPPURGBUPGGQC